TY - JOUR
T1 - P-tau/aβ42 and aβ42/40 ratios in csf are equally predictive of amyloid pet status
AU - Campbell, Michelle R.
AU - Ashrafzadeh-Kian, Susan
AU - Petersen, Ronald C.
AU - Mielke, Michelle M.
AU - Syrjanen, Jeremy A.
AU - van Harten, Argonde C.
AU - Lowe, Val J.
AU - Jack, Clifford R.
AU - Bornhorst, Joshua A.
AU - Algeciras-Schimnich, Alicia
N1 - Funding Information:
This study was supported by funding from the National Institutes of Health/National Institute on Aging grants U01 AG006786 and P30 AG062677, the GHR Foundation, Mayo Foundation for Medical Education and Research, and was made possible by the Rochester Epidemiology Project (R01 AG034676).
Funding Information:
R.C. Petersen is a consultant for Roche, Inc.; Biogen, Inc.; and Eisai, Inc. and is on a DSMB for Genentech. He receives funding for research from NIH. M.M. Mielke has consulted for Biogen and Brain Protection Company and receives research support from NIH and DOD. V.J. Lowe serves as a consultant for Bayer Schering Pharma, Life Molecular lmaging, Eisai, Inc., AVID Radiopharmaceuticals, and GE Healthcare and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). C.R. Jack serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from NIH and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Clinic.
Funding Information:
This study was supported by funding from the National Institutes of Health/National Institute on Aging grants U01 AG006786 and P30 AG062677, the GHR Foundation, Mayo Foundation for Medical Education and Research, and was made possible by the Rochester Epidemiology Project (R01 AG034676). R.C. Petersen is a consultant for Roche, Inc.; Biogen, Inc.; and Eisai, Inc. and is on a DSMB for Genentech. He receives funding for research from NIH. M.M. Mielke has consulted for Biogen and Brain Protection Company and receives research support from NIH and DOD. V.J. Lowe serves as a consultant for Bayer Schering Pharma, Life Molecular lmaging, Eisai, Inc., AVID Radiopharmaceuticals, and GE Healthcare and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). C.R. Jack serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from NIH and the Alexander Family Alzheimer?s Disease Research Professorship of the Mayo Clinic.
Publisher Copyright:
© 2021 The Authors.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Introduction: Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p-tau] and total tau [t-tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical and preclinical Alzheimer’s disease dementia (AD) from other neurodegenerative processes. Methods: CSF biomarkers were measured in 150 participants from the Mayo Clinic Study of Aging and the Alzheimer’s Disease Research Center. P-tau/Aβ42 (Roche Elecsys, Fujirebio LUMIPULSE) and Aβ42/40 (Fujirebio LUMIPULSE) ratios were compared to one another and to amyloid positron emission tomography (PET) classification. Results: Strong correlation was observed between LUMIPULSE p-tau/Aβ42 and Aβ42/40, as well as Elecsys and LUMIPULSE p-tau/Aβ42 and Aβ42/40 (Spearman’s ρ = –0.827, –0.858, and 0.960, respectively). Concordance between LUMIPULSE p-tau/Aβ42 and Aβ42/40 was 96% and between Elecsys p-tau/Aβ42 and both LUMIPULSE ratios was 97%. All ratios had > 94% overall, positive, and negative percent agreement with amyloid PET classification. Discussion: These data suggest that p-tau/Aβ42 and Aβ42/40 ratios provide similar clinical information in the assessment of amyloid pathology.
AB - Introduction: Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p-tau] and total tau [t-tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical and preclinical Alzheimer’s disease dementia (AD) from other neurodegenerative processes. Methods: CSF biomarkers were measured in 150 participants from the Mayo Clinic Study of Aging and the Alzheimer’s Disease Research Center. P-tau/Aβ42 (Roche Elecsys, Fujirebio LUMIPULSE) and Aβ42/40 (Fujirebio LUMIPULSE) ratios were compared to one another and to amyloid positron emission tomography (PET) classification. Results: Strong correlation was observed between LUMIPULSE p-tau/Aβ42 and Aβ42/40, as well as Elecsys and LUMIPULSE p-tau/Aβ42 and Aβ42/40 (Spearman’s ρ = –0.827, –0.858, and 0.960, respectively). Concordance between LUMIPULSE p-tau/Aβ42 and Aβ42/40 was 96% and between Elecsys p-tau/Aβ42 and both LUMIPULSE ratios was 97%. All ratios had > 94% overall, positive, and negative percent agreement with amyloid PET classification. Discussion: These data suggest that p-tau/Aβ42 and Aβ42/40 ratios provide similar clinical information in the assessment of amyloid pathology.
KW - Alzheimer’s disease dementia
KW - Amyloid beta 42/40
KW - Amyloid positron emission tomography
KW - Cerebrospinal fluid biomarkers
KW - Elecsys
KW - Immunoassay
KW - LUMIPULSE
KW - P-tau/Aβ42
UR - https://www.scopus.com/pages/publications/85108220902
U2 - 10.1002/dad2.12190
DO - 10.1002/dad2.12190
M3 - Article
C2 - 34027020
SN - 2352-8729
VL - 13
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 1
M1 - e12190
ER -
SDG 3 Good Health and Well-being